Fragile X mental retardation 1

Fragile X mental retardation 1
Emw · CC BY-SA 3.0 · source
Name	FMR1
Other symbols	FMRP
Location	Xq27.3
Organisms	Homo sapiens

Contents

Fragile X mental retardation 1 is a human gene encoding an RNA-binding protein associated with a trinucleotide repeat expansion disorder known as fragile X syndrome, first characterized in clinical studies at institutions such as Johns Hopkins Hospital, Massachusetts General Hospital, and Mayo Clinic. The gene was mapped and sequenced through collaborations involving researchers at Cold Spring Harbor Laboratory, Howard Hughes Medical Institute, and National Institutes of Health, and has been the focus of molecular studies at Harvard University, Stanford University, and University of Cambridge. Fragile X syndrome research intersects with genetic counseling at American College of Medical Genetics and Genomics, therapeutic development at National Institute of Mental Health, and advocacy by groups such as National Fragile X Foundation.

Gene and protein structure

The FMR1 gene resides on the long arm of the X chromosome at Xq27.3 and contains a 5' untranslated CGG trinucleotide repeat in exon 1 that is polymorphic in populations studied by teams at University of Oxford, University of California, San Francisco, and Karolinska Institutet. The normal allele typically harbors fewer than 45 CGG repeats, the premutation range (approximately 55–200 repeats) was characterized by geneticists at University of Toronto and Yale University, while the full mutation (>200 repeats) leads to gene silencing described in landmark reports from University of Cambridge and University College London. The encoded protein, FMRP, contains KH domains and an RGG box identified in structural studies at Max Planck Institute, ETH Zurich, and Salk Institute; these domains mediate RNA binding as demonstrated by laboratories at Massachusetts Institute of Technology, University of Pennsylvania, and Columbia University.

FMRP is an RNA-binding protein that regulates translation and transport of specific mRNAs in neurons, with functional characterization contributed by groups at Cold Spring Harbor Laboratory, University of California, San Diego, and Johns Hopkins University. Expression of FMR1 is highest in brain regions including hippocampus and cerebellum, as mapped in atlases from Allen Institute for Brain Science, NIH, and University of Barcelona; developmental regulation was studied at University of Chicago, McGill University, and University of Sydney. FMRP associates with polyribosomes and stress granules, a property explored by researchers at University of Texas Southwestern Medical Center, Institut Pasteur, and University of California, Berkeley, and influences synaptic plasticity mechanisms investigated at Salk Institute, Cold Spring Harbor Laboratory, and Rockefeller University.

Loss of FMRP causes fragile X syndrome, the most common inherited cause of intellectual disability, with clinical characterization reported from Boston Children's Hospital, Great Ormond Street Hospital, and Children's Hospital of Philadelphia. Premutation carriers are at risk for fragile X-associated tremor/ataxia syndrome (FXTAS) described by neurologists at University of British Columbia, Mayo Clinic, and Imperial College London, and for fragile X-associated primary ovarian insufficiency (FXPOI) studied at NIH, University of Edinburgh, and University of Groningen. Comorbid neuropsychiatric conditions including autism spectrum disorder have been documented in cohorts from Vanderbilt University Medical Center, Karolinska Institutet, and University of Washington, while genotype–phenotype correlations were analyzed by consortia at European Molecular Biology Laboratory, Wellcome Trust Sanger Institute, and Broad Institute.

Pathogenesis involves CGG repeat expansion–triggered hypermethylation of the FMR1 promoter and transcriptional silencing, mechanisms elucidated in molecular studies at Cold Spring Harbor Laboratory, Johns Hopkins University, and National Cancer Institute. RNA toxicity from elevated FMR1 mRNA in premutation carriers contributes to FXTAS through sequestration of RNA-binding proteins, a model supported by findings from University of California, Los Angeles, Weill Cornell Medicine, and University of Milan. Absence of FMRP disrupts regulation of synaptic protein synthesis, affecting mGluR-dependent plasticity characterized in experiments at Massachusetts Institute of Technology, Salk Institute, and Columbia University, and implicates downstream pathways including ERK and PI3K studied at University of Cambridge, Harvard Medical School, and University of Basel.

Diagnostic testing relies on PCR and Southern blot assays to determine CGG repeat size and methylation status, methodologies standardized by clinical laboratories at Mayo Clinic, Quest Diagnostics, and ARUP Laboratories. Carrier screening and newborn screening pilot programs have been implemented in settings such as Mount Sinai Health System, Rady Children's Hospital, and Children's National Hospital, guided by policy discussions involving American College of Medical Genetics, Centers for Disease Control and Prevention, and World Health Organization. Molecular diagnostic interpretation uses guidelines developed by experts at ACMG, European Society of Human Genetics, and International Society for Prenatal Diagnosis.

There is no cure for full mutation–mediated absence of FMRP; management focuses on educational interventions and symptomatic treatments provided at centers such as Kennedy Krieger Institute, St. Jude Children's Research Hospital, and Boston Children's Hospital. Targeted clinical trials exploring modulators of synaptic signaling (for example mGluR5 antagonists and GABAergic agents) have been conducted by pharmaceutical teams at Pfizer, Novartis, and Roche in collaboration with academic centers including Yale University and UCSF. Prognosis varies by mutation status and comorbidities, with long-term follow-up studies from University of Wisconsin School of Medicine and Public Health, Range of Motion Project, and Eunice Kennedy Shriver National Institute of Child Health and Human Development informing care pathways and genetic counseling provided through clinics at Johns Hopkins Hospital, Mayo Clinic, and Mount Sinai Hospital.

Category:Genes on human chromosome X Category:Neurological disorders